C4 Therapeutics, Inc. (CCCC)
NMS · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 11.2M | 11.0M | 6.2M | 6.6M |
| Operating Income | (23.7M) | (23.1M) | (27.8M) | (26.4M) |
| Net Income | (32.2M) | (20.5M) | (25.1M) | (23.6M) |
| Diluted EPS | $-0.44 | $-0.18 | $-0.20 | $-0.18 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 31.1M | 20.8M | 35.6M | 35.9M |
| Operating Income | (129.5M) | (139.0M) | (117.2M) | (104.5M) |
| Net Income | (128.2M) | (132.5M) | (105.3M) | (105.0M) |
| Diluted EPS | $-2.62 | $-2.67 | $-1.52 | N/A |